Ex vivo evaluation of prolidase loaded chitosan nanoparticles for the enzyme replacement therapy

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 1, 2008, Pages 58-65

  Colonna, Claudia ^a   Conti, Bice ^a   Perugini, Paola ^a   Pavanetto, Franca ^a   Modena, Tiziana ^a   Dorati, Rossella ^a   Iadarola, Paolo ^a   Genta, Ida ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cellular uptake studies; Chitosan nanoparticles; Cytotoxicity; Enzyme replacement therapy; Prolidase Deficiency

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CHITOSAN; NANOPARTICLE; PROLINE DIPEPTIDASE; PROTASAN G213; UNCLASSIFIED DRUG;

ARTICLE; AUTOSOMAL DISORDER; BIOCOMPATIBILITY; CAPILLARY ELECTROPHORESIS; CELL GROWTH; CELL STRUCTURE; CELL VIABILITY; CONFOCAL MICROSCOPY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REPLACEMENT; EVALUATION; EX VIVO STUDY; HUMAN; HUMAN CELL; INTERNALIZATION; PARTICLE SIZE; PROLINE DIPEPTIDASE DEFICIENCY; QUANTITATIVE ANALYSIS; SKIN FIBROBLAST; ZETA POTENTIAL;

AMINO ACID METABOLISM, INBORN ERRORS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DIPEPTIDASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; ELECTROPHORESIS, CAPILLARY; ENDOCYTOSIS; ENZYME STABILITY; FIBROBLASTS; HUMANS; MICROSCOPY, CONFOCAL; NANOPARTICLES; PARTICLE SIZE; SOLUBILITY; TIME FACTORS;

EID: 50149099948     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.04.014     Document Type: Article

References (23)

1. Ravi Kumar M.N.V. A review of chitin and chitosan applications. React. Funct. Polym. 46 (2000) 1-27
2. Minagawa T., Okamura Y., Shigemasa Y., Minami S., and Okamoto Y. Effects of molecular weight and deacetylation degree of chitin/chitosan on wound healing. Carbohydr. Polym. 67 (2007) 640-644
3. Mi F.L., Tan Y.C., Liang H.F., and Sung H.W. In vivo biocompatibility and degradability of a novel injectable-chitosan-based implant. Biomaterials 23 (2002) 181-191
4. Agnilotri S.A., Mallikarjuna N.N., and Aminabhavi T.M. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J. Control. Release 100 (2004) 5-28
5. Janes K.A., Fresneau M.P., Marazuela A., Fabra A., and Alonso M.J. Chitosan nanoparticles as delivery systems for doxorubicin. J. Control. Release 73 (2001) 255-267
6. Janes K.A., Calvo P., and Alonso M.J. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Deliv. Rev. 47 (2001) 83-97
7. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., and Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 51 (2001) 81-96
8. Mansouri S., Lavigne P., Corsi K., Benderdour M., Beaumont E., and Fernandes J.C. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. Eur. J. Pharm. Biopharm. 57 (2004) 1-8
9. Schipper N.G.M., Olsson S., Hoogstraate J.A., deBoer A.G., Varum K.M., and Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm. Res. 14 7 (1997) 923-929
10. Peppas N.A., and Huang Y. Nanoscale technology of mucoadhesive interactions. Adv. Drug Deliv. Rev. 56 (2004) 1675-1687
11. Ma Z., and Lim L.-Y. Uptake of chitosan and associated insulin in Caco-2 cell monolayers: a comparison between chitosan molecules and chitosan nanoparticles. Pharm. Res. 20 11 (2003) 1812-1819
12. Harush-Frenkel O., Debotton N., Benita S., and Altschuler Y. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem. Biophys. Res. Commun. 353 (2007) 26-32
13. Myara L., Charpentier C., and Lemonnier A. Prolidase and prolidase deficiency. Life Sci. 34 (1984) 1985-1998
14. In: Royce P.M., and Steinmann B. (Eds). Connective Tissue and its Heritable Disorders (2002), Wiley-Liss, New York 727-743
15. Viglio S., Annovazzi L., Conti B., Genta I., Perugini P., Zanone C., Casado B., Cetta G., and Iadarola P. The role of emerging techniques in the investigation of prolidase deficiency from diagnosis to the development of a possible therapeutical approach. J. Chromatogr. B 832 (2006) 1-8
16. Lupi A., Perugini P., Genta I., Modena T., Conti B., Casado B., Cetta G., Pavanetto F., and Iadarola P. Biodegradabile microspheres for prolidase delivery to human cultured fibroblasts. J. Pharm. Pharmacol. 56 (2004) 597-603
17. Perugini P., Hassan K., Genta I., Modena T., Pavanetto F., Cetta G., Zanone C., Iadarola P., Asti A., and Conti B. Intracellular delivery of liposome-encapsulated prolidase in cultured fibroblasts from prolidase-deficient patients. J. Control. Release 102 (2005) 181-190
18. Colonna C., Conti B., Perugini P., Pavanetto F., Modena T., and Genta I. Chitosan glutamate nanoparticles for protein delivery: development and effect on prolidase stability. J. Microencapsulation 24 (2007) 553-564
19. Muzzarelli R.A.A. The colorimetric determination of chitosan. Anal. Biochem. 260 (1998) 255-257
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
21. Hartree E.E. Determination of protein: a modification of Lowry method that gives a linear photometric response. Anal. Biochem. 48 (1972) 422-427
22. Forlino A., Lupi A., Vaghi P., Icaro Cornaglia A., Calligaro A., Campari E., and Cetta G. Mutation analysis of five new patients affected by prolidase deficiency: the lack of enzyme activity causes necrosis-like cell death in cultured fibroblasts. Hum. Genet. 111 (2002) 314-322
23. Huang M., Khor E., and Lim L.-Y. Uptake and cytotoxicity of chitosan molecules ad nanoparticles: effects of molecular weight and degree of deacetylation. Pharm. Res. 21 2 (2004) 344-353